BRIEF—Almirall’s Ilumetri effective after a year in psoriasis

Spanish dermatology specialist Almirall has announced new data from the POSITIVE real-world evidence study demonstrating that Ilumetri (tildrakizumab) effectively restores the level of wellbeing of patients with moderate-to-severe plaque psoriasis to those of the general population as early as week 16 after starting treatment.

In the study, this fundamental benefit was shown to be maintained for up to one year of treatment. These interim results on the impact of Ilumetri on patient-reported outcomes and skin clearance in people with moderate-to-severe psoriasis, were presented for the first time at the International Federation of Psoriasis Associations Conference 2024 

Volker Koscielny, chief medical officer at Almirall, said: “These findings represent a significant milestone in our ongoing efforts to address the needs of patients and dermatologists to treat chronic dermatological conditions and help improve the patients’ health and wellbeing.

“The POSITIVE study demonstrates not only the efficacy of Ilumetri in clearing skin but also its impact on enhancing patients' overall wellbeing, which ultimately can contribute to the successful treatment enabling patients to get their lives back.”